Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium.
Kuhn L., Barnabas S., Cotugno N., Peay H., Goulder P., Cotton M., Violari A., Pahwa S., Reddy K., Tagarro A., Otwombe K., Fry S., Vaz P., Lain MG., Nhampossa T., Archary M., Maiga AI., Puthanakit T., Kityo CM., Foster C., Rojo P., Klein N., Nastouli E., Tiemessen CT., de Rossi A., Ndung'u T., Persaud D., Lichterfeld M., Giaquinto C., Palma P., Rossi P., EPIICAL consortium None.
Analytical treatment interruption (ATI) is widely acknowledged as an essential component of studies to advance our understanding of HIV cure, but discussion has largely been focused on adults. To address this gap, we reviewed evidence related to the safety and utility of ATI in paediatric populations. Three randomised ATI trials using CD4 T-cell and clinical criteria to guide restart of antiretroviral therapy (ART) have been conducted. These trials found low risks associated with ATI in children, including reassuring findings pertaining to neurocognitive outcomes. Similar to adults treated during acute infection, infants treated early in life have shifts in virological and immunological parameters that increase their likelihood of achieving ART-free viral control. Early ART limits the size and diversity of the viral reservoir and shapes effective innate and HIV-specific humoral and cellular responses. Several cases of durable ART-free viral control in early treated children have been reported. We recommend that, where appropriate for the study question and where adequate monitoring is available, ATI should be integrated into ART-free viral control research in children living with HIV. Paediatric participants have the greatest likelihood of benefiting and potentially the most years to prospectively realise those benefits. Excluding children from ATI trials limits the evidence base and delays access to interventions.